



PRESS RELEASE

Published 21-04-2021

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Asarina Pharma AB (publ) (“Asarina Pharma”) on 21 April 2021 in Stockholm. The CEO’s presentation is available at the company’s website.

Adoption of income statement and balance sheet and discharge from liability

The AGM resolved to adopt the income statement for the financial year 2020 as well as the balance sheet and consolidated balance sheet as of 31 December 2020. The members of the Board of Directors and the managing director were discharged from liability for the financial year 2020.

Allocation of profit or loss

The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2020 and that the results of the company shall be carried forward.

Board of Directors and auditor

The AGM resolved, in accordance with the nomination committee’s proposal, on re-election of Paul de Potocki, Erin Gainer and Marianne Kock as board members. Paul de Potocki was re-elected as the chairman of the Board of Directors. The AGM re-elected the audit firm Ernst & Young Aktiebolag as auditor.

The AGM further resolved on remuneration to the Board of Directors in accordance with the nomination committee’s proposal. The AGM furthermore resolved in accordance with the nomination committee’s proposal, that remuneration to the auditor shall be paid in accordance with approved statement of costs.

Nomination committee for the next annual general meeting

The AGM resolved, in accordance with the nomination committee’s proposal, that the principles for the appointment of the nomination committee adopted at the AGM 2020 shall continue to apply also for the appointment of the nomination committee ahead of the AGM 2022.

Authorisation to issue new shares

The AGM resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors to, at one or several occasions and for the period up until the next annual general meeting, resolve to increase the company’s share capital by issuing new shares. Such issue resolution may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions.

The total number of shares that may be issued with deviation from the shareholders’ preferential rights shall be limited to 15 percent of the number of shares in the company. The total number of shares that may be issued with preferential rights for the shareholders shall not be limited in any other way than what follows from the articles of association of the company.

Amendment of the articles of association

The AGM resolved, in accordance with the Board of Directors' proposal, to amend the articles of association.

Incentive programme

The AGM resolved, in accordance with the Board of Directors' proposal, to adopt an incentive programme to employees and consultants consisting of warrants. In short, the incentive programme includes an issue of not more than 700,000 warrants. Each warrant entitles the holder to subscribe for one share in Asarina Pharma during the time period commencing on 15 May 2023 up to and including 31 May 2023.

For further information, please contact:

Peter Nordkild, CEO

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO

Phone: +45 5132 3698

E-mail: jakob.dynnes@asarinapharma.com

Certified Adviser

Erik Penser Bank AB

Phone: +46 8-463 83 00

Mail: certifiedadviser@penser.se

About Asarina Pharma

We are a Swedish biotech company developing Sepranolone for allopregnanolone-related stress, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSAs compounds (GABA_A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

The information above was released for publication by the contact persons set out above, on April 21 at 11.00 CEST.